IGC Pharma, Inc.
IGCAMEXHealthcare● Active
$0.30
+$0.01(+4.55%)
Market Cap$29927209
P/E Ratio—
52W High$0.5
52W Low$0.24
IGC Pharma, Inc. (IGC) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IGC · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.19M | $1.27M | $1.34M | $0.91M | $0.40M |
| Cost of Revenue | $0.83M | $0.65M | $0.61M | $1.07M | $0.20M |
| Gross Profit | $0.35M | $0.62M | $0.73M | ($0.16M) | $0.19M |
| Gross Margin %(computed) | 29.68% | 48.70% | 54.50% | -17.34% | 48.87% |
| Operating Expenses | |||||
| R&D Expenses | $5.19M | $3.65M | $3.77M | $3.46M | $2.33M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $10.55M | $8.06M | $10.53M | $11.41M | $15.62M |
| Operating Income | ($10.20M) | ($7.45M) | ($9.80M) | ($11.57M) | ($15.43M) |
| Operating Margin %(computed) | -860.29% | -585.84% | -728.48% | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($6.55M) | ($7.12M) | ($13.00M) | ($11.51M) | ($15.02M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($6.55M) | ($7.12M) | ($13.00M) | ($11.51M) | ($15.02M) |
| Net Margin %(computed) | -552.11% | -560.27% | -966.54% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.07 | $-0.09 | $-0.22 | $-0.22 | $-0.30 |
| Wtd Avg Shares | 95.04M | 76.52M | 58.84M | 52.58M | 49.99M |
| EBITDA | ($9.88M) | ($6.98M) | ($9.16M) | ($10.85M) | ($14.37M) |
| EBITDA Margin %(computed) | -832.97% | -549.33% | -681.12% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more IGC Pharma, Inc. data
About IGC Pharma, Inc. (IGC) Income Statement
IGC Pharma, Inc. (IGC) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2026, IGC reported revenue of $0.00B, gross profit of $0.00B (gross margin 29.68%), and net income of ($0.01B) — a net profit margin of -552.11%.
Frequently asked questions
IGC · 4 questionsIGC Pharma, Inc. (IGC) reported revenue of $0.00B for 2026, down 6.7% year-over-year.
IGC revenueIGC salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09